Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 18 2024
0mins
Source: Benzinga
Funding Increase Announcement: Awakn Life Sciences Corp. has expanded its private placement financing from $1 million to $2 million due to increased investor interest, securing an additional $394,286 in the latest tranche, bringing total funds raised to $1,117,142.
Focus on Alcohol Use Disorder: The company aims to use the proceeds to advance research and development for treatments targeting Alcohol Use Disorder (AUD), addressing a significant market need affecting millions of adults in the U.S. and Europe.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
